3 completed, 2 not yet recruiting. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Not yet recruiting 2 |
Follow Autotelicbio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants ATB-U101, ATB-1011, ATB-U1011 - Diabete Type 2, Hypertension | Phase 1 | Not yet recruiting | Autotelicbio | 36 | 2026-05-18 | 2026-05-15 |
| Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors ATB-320 - Solid Tumors | Phase 1 | Not yet recruiting | Autotelicbio | 24 | 2025-12-01 | 2025-10-01 |
| Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 ATB-101, ATB-1011, ATB-1012 - Healthy Adult Volunteers | Phase 1 | Completed | Autotelicbio | 36 | 2021-06-19 | 2024-01-31 |
| Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers Olmesartan, Dapagliflozin - Healthy Adult Volunteers | Phase 1 | Completed | Autotelicbio | 38 | 2021-03-30 | 2021-09-05 |
| TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor TASO-001((TGF-β2 targeting anti-sense oligonucleotide), Aldesleukin - Solid Tumor | Phase 1 | Completed | Autotelicbio | 9 | 2021-03-09 | 2024-01-31 |
Diabetes Mellitus, Type 2 (1) · Hypertension (1)
aldesleukin (1) · dapagliflozin (1) · olmesartan (1)
South Korea (3)
Jaewoo Kim (1) · James Jun, M.D. (1) · KyungWan Nam, Pharm. D. (1)